Monthly Archives: August 2019

Tilray to acquire adult-use cannabis retailer FOUR20

Tilray acquisition of FOUR20 : Tilray, a Canadian pharmaceutical and cannabis company, through its wholly-owned subsidiary High Park Holdings has agreed to acquire 420 Investments (FOUR20) in an all-stock transaction valued at C$110 million. US-based FOUR20 is an adult-use cannabis retail operator which offers retail experience on high-quality product selection, education, and community to adult-use […]

Conn’s HomePlus to open two new stores in Birmingham, AL next month

US specialty retailer Conn’s HomePlus will open two new showrooms next month in Birmingham, Alabama, bringing total operating units to 135 across 14 states. The two new Birmingham locations located at 9530 Parkway East Roebuck and in Wildwood Centre, 251 Lakeshore Parkway mark third and fourth Conn’s HomePlus showrooms in Alabama. The stores follow the new Montgomery showroom, opened April 2019 […]

Orkney Distillery to explore feasibility of hydrogen fuel to decarbonize distilling process

The HySpirits project : Orkney Distilling, Edinburgh Napier University, and the European Marine Energy Centre (EMEC) have partnered to explore the feasibility of hydrogen fuel to decarbonize the distilling process at environmentally friendly gin distillery under The HySpirits project. The project will study the potential conversion of a craft gin distillery in Orkney in Scotland […]

Jordan Company divests DuBois Chemicals assets to Altas Partners

Altas Partners, a Canadian investment company, has entered into a definitive agreement with The Jordan Company to acquire DuBois Chemicals, a specialty chemical supplier, for an undisclosed amount. DuBois provides mission-critical and innovative products to more than 15,000 customers worldwide by integrating local high-touch technical service, strong R&D capabilities, customized equipment solutions, and manufacturing expertise. […]

MERU clinical trial : AbbVie ends Rova-T program in lung cancer

Following undesired results from the phase 3 MERU clinical trial, US biopharma company AbbVie has terminated the research and development program of Rovalpituzumab Tesirine (Rova-T), an investigational lung cancer drug. The MERU clinical trial is being closed over futility with the phase 3 study, which was assessing Rova-T as a first-line maintenance therapy for advanced […]

The post MERU clinical trial : AbbVie ends Rova-T program in lung cancer appeared first on PharmaNewsDaily.com.

Scroll To Top